on Applied DNA Sciences, Inc.
Applied DNA Repositions TR8 PGx Test Post-FDA Announcement
Applied DNA Sciences, Inc. announced a strategic shift for its pharmacogenomics testing service, TR8™ PGx. The company now offers specific subpanels alongside full panel testing. This change aims to address genetic variants of the DPYD gene linked to deficiencies in metabolizing fluoropyrimidine drugs like capecitabine and fluorouracil, both critical in cancer therapies.
This move comes after the FDA's warning about potential toxicity in patients with certain DPYD variants. Applied DNA's TR8 PGx test, approved by New York State, helps identify individuals at risk. The company targets enhancing its service's adoption, specifically in oncology, cardiology, and psychiatry, to better guide clinical decisions and improve patient outcomes.
Dr. James A. Hayward, CEO of Applied DNA, emphasized the importance of genetic testing in treatment decisions. The TR8 PGx test offers insights into how patients might respond to various drugs, potentially enhancing treatment efficacy and safety.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Applied DNA Sciences, Inc. news